
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a preclinical stage biotechnology company with a promising technology stack utilizing AI-guided epitope-steering and monoclonal antibody optimization to minimize development risks, and its anti-Activin E antibody for obesity and cardiometabolic disease, IBIO-610, reported near-complete inhibition of Activin E after 8 weeks with positive clinical data compared to competitors. With multiple clinical asset candidates and a strong development pipeline, iBio faces competition and risks associated with clinical trials; however, with a probability of success of 5-20% and a WACC of 17%, our NPV analysis establishes our 12-month price target of $5 per share to capture the upside potential.
Bears say
iBio is highly dependent on future fundraising and their limited revenue-generating products puts them at risk of not achieving their target stock price. Additionally, legal expenses, competition, and potential infringement lawsuits could have a negative impact on their financial performance and valuation. Along with the potential need for future fundraising and potential dilution of stockholders, these factors should be taken into consideration by investors when evaluating iBio's stock.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares